Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook 

Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook 

ReutersReuters2026/07/30 11:01


Overview

  • U.S. laboratory services provider's Q2 revenue up 5.8%, slightly beating analyst expectations

  • Adjusted EPS for Q2 rose 14.9% to $4.99

  • Company raised 2026 revenue growth and adjusted EPS guidance, boosted share buyback by $1.0 bln


Outlook

  • Labcorp raises 2026 enterprise revenue growth guidance to 5.4%-6.3%

  • Company expects 2026 adjusted EPS between $18.10 and $18.55


Result Drivers

  • ORGANIC GROWTH AND OPERATING EFFICIENCIES - Co said increases in adjusted operating income and margin were due to organic growth and operating efficiencies

  • ONCOLOGY AND SPECIALTY TESTING - Co cited expansion in oncology offerings and high-growth specialty areas as drivers of business momentum

  • ACQUISITIONS AND NEW TEST LAUNCHES - Co said acquisitions and launches of new diagnostic tests, including nationwide rollout of ColoSense and new genetic health panels, contributed to growth


Company press release: ID:nPnb5RLPXa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Slight Beat*

$3.73 bln

$3.71 bln (14 Analysts)

Q2 Adj EPS from Cont Ops

$4.99

Q2 EPS from Cont Ops

$3.64

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities services peer group is "buy"

  • Wall Street's median 12-month price target for Labcorp Holdings Inc is $320.00, about 4.2% above its July 29 closing price of $307.15

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook

  • July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength

  • July 28 - IQVIA Q2 revenue beats estimates; outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI "chip inflation" sweeps through the UK economy

The UK’s July CPI is expected to rise by 2.9% year-on-year, marking the first acceleration in four months. In addition to a jump in energy bills due to the reset of Ofgem’s price cap, an AI-driven memory chip shortage is emerging as a new driver of inflation—Apple laptops, tablets, and Xbox consoles have all announced price increases.

华尔街见闻2026/08/16 07:46